Bank of New York Mellon’s Tourmaline Bio TRML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-49,964
| Closed | -$2.39M | – | 4288 |
|
|
2025
Q3 | $2.39M | Sell |
49,964
-6,707
| -12% | -$186K | ﹤0.01% | 2708 |
|
|
2025
Q2 | $906K | Sell |
56,671
-4,049
| -7% | -$65.6K | ﹤0.01% | 3180 |
|
|
2025
Q1 | $924K | Sell |
60,720
-539
| -0.9% | -$8.64K | ﹤0.01% | 3116 |
|
|
2024
Q4 | $1.24M | Sell |
61,259
-179
| -0.3% | -$4.51K | ﹤0.01% | 3023 |
|
|
2024
Q3 | $1.58M | Sell |
61,438
-9,259
| -13% | -$155K | ﹤0.01% | 2870 |
|
|
2024
Q2 | $909K | Buy |
+70,697
| New | +$1.14M | ﹤0.01% | 3262 |
|
|
2023
Q4 | – | Sell |
-2,069
| Closed | -$58.1K | – | 4384 |
|
|
2023
Q3 | $58.1K | Hold |
2,069
| – | – | ﹤0.01% | 4151 |
|
|
2023
Q2 | $62.9K | Sell |
2,069
-3,787
| -65% | -$96.7K | ﹤0.01% | 4139 |
|
|
2023
Q1 | $110K | Hold |
5,856
| – | – | ﹤0.01% | 4057 |
|
|
2022
Q4 | $59.7K | Sell |
5,856
-725
| -11% | -$11.7K | ﹤0.01% | 4210 |
|
|
2022
Q3 | $173K | Buy |
6,581
+712
| +12% | +$25.9K | ﹤0.01% | 4065 |
|
|
2022
Q2 | $265K | Sell |
5,869
-93
| -2% | -$7.34K | ﹤0.01% | 3943 |
|
|
2022
Q1 | $586K | Buy |
5,962
+620
| +12% | +$58K | ﹤0.01% | 3621 |
|
|
2021
Q4 | $817K | Buy |
5,342
+2,600
| +95% | +$385K | ﹤0.01% | 3500 |
|
|
2021
Q3 | $372K | Buy |
2,742
+1,064
| +63% | +$146K | ﹤0.01% | 3957 |
|
|
2021
Q2 | $246K | Buy |
+1,678
| New | +$257K | ﹤0.01% | 4032 |
|
Bank of New York Mellon's TRML Position: Q4 2025 in Review
Bank of New York Mellon sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 49,964 shares — an estimated $2.39M sold.
Bank of New York Mellon first reported a position in TRML in Q2 2021 and held it in 16 quarters. The position peaked at $2.39M in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.
- Bank of New York Mellon reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
- Bank of New York Mellon sold 49,964 Tourmaline Bio shares in Q4 2025, an estimated $2.39M.
- Bank of New York Mellon first reported a position in Tourmaline Bio in Q2 2021 and held it in 16 quarters.
- Bank of New York Mellon's Tourmaline Bio position peaked at $2.39M in Q3 2025.
- 0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.
Based on Bank of New York Mellon's 13F filing for Q4 2025, filed 10 Feb 2026.